Patents by Inventor Qiaodong WEN

Qiaodong WEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PD-L1 antagonist compound
    Patent number: 12091398
    Abstract: Provided is a compound represented by formula (I) and a pharmaceutical composition thereof, as well as a method for using a compound represented by formula (I) to prevent and/or treat immune-related disorders.
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: September 17, 2024
    Assignee: ADLAI NORTYE BIOPHARMA CO., LTD.
    Inventors: Pan Li, Beidi Xu, Qiaodong Wen, Enguang Feng, Ji Wang, Yang Lu, Yu Zhou, Zhiyong Yu, Zhiying Huang
  • HIGH ACTIVITY HPK1 KINASE INHIBITOR
    Publication number: 20230399327
    Abstract: A compound of formula (I) having the activity of inhibiting HPK1 kinase and a pharmaceutical composition comprising the compound. Also provided are the use of the compound in the prevention and/or treatment of cancers, tumors, inflammatory diseases, autoimmune diseases or immune-mediated diseases.
    Type: Application
    Filed: October 26, 2021
    Publication date: December 14, 2023
    Applicant: ADLAI NORTYE BIOPHARMA CO., LTD.
    Inventors: Yufeng CHEN, Canfeng LIU, Meng LV, Qiaodong WEN, Yongqiang SHI, Peng WU, Kaixuan CHEN, Han YANG, Wanli CHENG, Youping WANG, Pingping LU, Nanhai HE
  • PD-L1 ANTAGONIST COMPOUND
    Publication number: 20230054028
    Abstract: Provided are a compound of Formula (I) and a pharmaceutical composition thereof, as well as a method for using the compounds of Formula (I) to prevent and/or treat immune-related disorders.
    Type: Application
    Filed: December 22, 2020
    Publication date: February 23, 2023
    Applicant: ADLAI NORTYE BIOPHARMA CO., LTD.
    Inventors: Zhiyong YU, Pan LI, Beidi XU, Yu ZHOU, Wei PANG, Qiaodong WEN, Yongqiang SHI, Zhao SUN, Meng LV
  • PD-L1 ANTAGONIST COMPOUND
    Publication number: 20220227733
    Abstract: Provided is a compound represented by formula (I) and a pharmaceutical composition thereof, as well as a method for using a compound represented by formula (I) to prevent and/or treat immune-related disorders.
    Type: Application
    Filed: February 20, 2020
    Publication date: July 21, 2022
    Applicant: ADLAI NORTYE BIOPHARMA CO., LTD.
    Inventors: Pan LI, Beidi XU, Qiaodong WEN, Enguang FENG, Ji WANG, Yang LU, Yu ZHOU, Zhiyong YU, Zhiying HUANG
  • Indoleamine 2,3-dioxygenase inhibitors and use of same in medicine
    Patent number: 11111230
    Abstract: The present invention relates to a compound represented by formula I, a pharmaceutical composition containing the compound of formula I, a method for inhibiting indoleamine 2,3-dioxygenase, and its use in medicine.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: September 7, 2021
    Assignee: ADLAI NORTYE BIOPHARMA CO., LTD.
    Inventors: Pan Li, Qiaodong Wen, Ji Wang, Quan Gan, Yang Lu, Donghui Yang
  • INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND USE OF SAME IN MEDICINE
    Publication number: 20200331887
    Abstract: The present invention relates to a compound represented by formula I, a pharmaceutical composition containing the compound of formula I, a method for inhibiting indoleamine 2,3-dioxygenase, and its use in medicine.
    Type: Application
    Filed: June 26, 2020
    Publication date: October 22, 2020
    Inventors: Pan LI, Qiaodong WEN, Ji WANG, Quan GAN, Yang LU, Donghui YANG